Financials
Financial year 2025
Gross margin
€ 0
Profit
Healthy€ 383.4 million
▼ 2% vs 2024
Debts
Low€ 3,296.8 million
▼ 20% vs 2024
U C B from Anderlecht, company number BE0403053608, closed financial year 2025 with a result of € 383.4 million after tax. For that financial year U C B recorded a gross margin of € 0 and equity of € 9,160.3 million. Compared with financial year 2024, the result moved from € 389.6 million to € 383.4 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.
What happened at U C B?
What happened at U C B in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stefaan HEYLEN stepped down as director. NBB
- Jonathan PEACOCK stepped down as director. NBB
- Fiona POWRIE stepped down as director. NBB
- Ulf WIINBERG stepped down as director. NBB
- Rodolfo SAVITZKY stepped down as director. NBB
- Nefertiti GREENE stepped down as director. NBB
- Dolca THOMAS stepped down as director. NBB
- Pierre GURDJIAN stepped down as director. NBB
In short
From € 313.1 million profit in 2021 to € 383.4 million profit in 2025.
Paid € 6 million in corporate taxes since 2021.
Best year ever: 2024, with € 389.6 million profit.
Paid out € 1,298.9 million in dividends to the owners in total.
A new publication or filing at U C B? We notify you, reason included.
Follow U C BNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of UCB (Investments) LTD, 100% of UCB Pharma Romania SRL, 100% of UCB Pharma SA, 100% of UCB Trading (Shanghai) Ltd., 100% of UCB Bulgaria EOOD and 100% of UCB Pharma Logistics LLC itself.
Directors
According to the 2025 annual accounts
Maëlys CASTELLA
Director
since 2023 · until 2027
Ulf WIINBERG
Director
since 2024 · until 2028
Jan BERGER
Director
since 2023 · until 2027
Jean-Christophe TELLIER
Director
since 2022 · until 2026
Rodolfo SAVITZKY
Director
since 2024 · until 2028
Kay DAVIES
Director
since 2022 · until 2026
Nefertiti GREENE
Director
since 2024 · until 2028
Cédric van RIJCKEVORSEL
Director
since 2022 · until 2026
Stefaan HEYLEN
Director
since 2025 · until 2029
Dolca THOMAS
Director
since 2024 · until 2028
Jonathan PEACOCK
Chairman of the board
since 2025 · until 2029
Pierre GURDJIAN
Director
since 2024 · until 2028
Charles-Antoine JANSSEN
Director
since 2024 · until 2028
Fiona POWRIE
Director
since 2026 · until 2029
Cyril JANSSEN
Director
since 2023 · until 2027
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
UCB Belgium
UCB PHARMA same network
€ 4,622.6 million revenue · 2025
UCB Fipar
Fondation Emmanuel Janssen
UCB BIOPHARMA
€ 3,642.1 million revenue · 2025
+5 more
Details
- Company number
- 0403.053.608
- VAT number
- BE 0403.053.608
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- U C B
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 May 1925
- Peppol
- Active · Active since 24 Dec 2025
- Activities · NACE
Managementactiviteiten van holdings
Activiteiten van holdings
Overige zakelijke dienstverlening, neg
Overige zakelijke dienstverlening, n.e.g.
Holdings
Vervaardiging van geneesmiddelen